top of page
ViAqua Therapeutics was established to address the growing need for effective, specific, and affordable health management of diseases in aquaculture. ViAqua is developing a biotechnology-based, oral delivery platform for targeted administration of nucleic acid-based therapeutics. ViAqua’s first product is an RNA-based solution for application against the White Spot Shrimp Virus (WSSV) pandemic.
LEADERSHIP
ARTICLES
06/20/20
Congratulations to our World Economic Forum Technology Pioneers 2020
Sanjeev Krishnan, S2G Ventures Managing Director and CIO, will ...Connecting Technology and Business to Create Healthy, Resilient Food Systems.
IN THE NEWS
PODCAST
VIEW MORE COMPANIES
bottom of page